Sequenom among recipients of FDA letter about genetic testing Print E-mail
By Staff and Wire Reports   
Thursday, 22 July 2010 09:13
Interleukin Genetics Inc.(AMEX: ILI), Sequenom (NasdaqGM: SQNM) and CyGene Laboratories Inc. (OTC: CYGE.PK) are among 13 makers of genetic tests sold directly to consumers told by U.S. regulators that their products may be medical devices needing federal approval, according to a report from Bloomberg.

The U.S. Food and Drug Administration sent letters to the companies saying the tests “appear to meet the definition of a device.” Interleukin doesn’t believe its tests are devices and will provide information to regulators to support its position, the Waltham, Massachusetts-based company said today in a regulatory filing.

The FDA sent similar letters in May to makers of gene- testing kits such as Mountain View, California-based 23andMe Inc. and San Diego-based Pathway Genomics that offer their services to the public. Agency officials have said they intend to regulate the area more closely and require test-makers to prove their products are effective and provide useful information.

Interleukin sells tests through the company’s website to help consumers learn about their heart health and choose diets that best fit them based on their individual genes.

CyGene offers “personal DNA testing that makes a difference” to help consumers learn if they have genetic predispositions to visions disorders including glaucoma and macular degeneration and heart problems, diabetes and obesity, the Coral Springs, Florida-based company said on its website.

Sequenom Inc., which markets prenatal diagnostic tests through doctors to help pregnant women learn if their unborn children have genetic abnormalities that may lead to birth defects may meet the definition of a device subject to federal review.

The U.S. House of Representatives Energy and Commerce Committee is scheduled to conduct a hearing tomorrow on gene- testing services.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter